| ORIGINAL ARTICLE |
|
| Year : 2017 | Volume
: 16
| Issue : 3 | Page : 186-191 |
|
|
A comparative study of 68Gallium-prostate specific membrane antigen positron emission tomography-computed tomography and magnetic resonance imaging for lymph node staging in high risk prostate cancer patients: An initial experience
Manoj Gupta1, Partha S Choudhury1, Dibyamohan Hazarika2, Sudhir Rawal3
1 Department of Nuclear Medicine, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
2 Department of Radiology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
3 Department of Uro Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
Correspondence Address:
Manoj Gupta
Department of Nuclear Medicine, Rajiv Gandhi Cancer Institute and Research Centre, Sector 5, Rohini, New Delhi - 110 085
India
  | Check |
DOI: 10.4103/1450-1147.207272 PMID: 28670175 
|
|
|
Lymph node staging plays an important role in planning initial management in nonmetastatic prostate cancer. This article compares the role of 68Gallium (68Ga)-prostate specific membrane antigen (PSMA) positron emission tomography-computed tomography (PET-CT) with magnetic resonance imaging (MRI), which is considered the standard staging modality. Out of 39 high-risk prostate cancer patients who underwent 68Ga-PSMA PET-CT for staging (December 2014–December 2015), 12 patients underwent radical prostatectomy along with ePLND and were included in the analysis. Findings of the PSMA PET and MRI were compared with final histopathology. Sensitivity, specificity, positive predicative value (PPV), negative predicative value (NPV), and accuracy of 68Ga-PSMA PET-CT and MRI were calculated for numbers of patients and pelvic lymph node metastasis. Chi-square test, McNemar's test, and receiver operating characteristic (ROC) analysis were also done. 68Ga-PSMA PET-CT and MRI sensitivity, specificity, PPV, NPV, and accuracy for number of patients detection were 100%, 80%, 87.5%, 100%, 91.67%, and 57.14%, 80%, 80%, 57.4%, 66.67%, respectively. For detection of metastatic lymph node, it was 66.67%, 98.61%, 85.71%, 95.95%, 95.06% and 25.93%, 98.61%, 70%, 91.42%, 90.53%, respectively. Difference of lymph nodal detectability was statistically significant on Chi-square test. On McNemar's test,P value was statistically insignificant for number of patient detection (P = 0.250) but statistically significant for lymph nodal detection (P = 0.001) for 68Ga-PSMA PET-CT. In ROC analysis, area under the curve was also significantly high for lymph node detectability by 68Ga-PSMA PET-CT. Our initial experience shows that 68GaPSMA PET-CT is a very promising tracer for N staging in the initial workup of prostate cancer. It has the potential to impact patient's initial management and can up- and down-stage effectively. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
Users Online: 628 
